Abstract: Embodiments described herein relate to systems and methods for testing integrated circuit devices within an environment that is representative of the application environment in which an integrated circuit device will be used. In at least one embodiment, the testing system comprises a second reference integrated circuit device that provides flexibility in testing, allowing only the input to a first reference integrated circuit device of an application system to be tapped and not necessarily both input to and output from the first reference integrated circuit device to be tapped. In some embodiments, the input to the first reference integrated circuit device may be subsequently modified by a controller.

Abstract: A system and method for testing an integrated circuit module including multiple integrated circuit devices that provide a data strobe signal associated with at least one data signal provided by the same integrated circuit device. A determination of a test outcome for the integrated circuit module may be made after identifying data valid windows for each integrated circuit device, without having to both identify a common sampling window defined by an intersection of the identified data valid windows and verify that such common sampling window meets specification requirements.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection.

Abstract: Embodiments described herein relate to systems and methods for testing integrated circuit devices within an environment that is representative of the application environment in which an integrated circuit device will be used.

Abstract: Embodiments of an apparatus and method for high-speed testing of a device under test are described herein, where the device under test is coupled to a tester via a limited passband communication channel. A plurality of test vector patterns is generated having characteristics such that when a given test vector pattern is transmitted electrically at a transmission rate via the communication channel, the test vector pattern has a frequency content that is less than the frequency content of a high frequency test vector pattern if the high frequency test vector pattern were to be transmitted electrically at the transmission rate via the communication channel, and such that the frequency content of each test vector pattern when transmitted electrically at the transmission rate via the communication channel falls within the passband associated with the communication channel.

Abstract: The invention relates to a polyimide resin polymer which contains at least one repeating unit selected from those of formula (A-1) and formula (A-2) below as polymerization units, wherein P1, P2, Q1, and Q2 are as defined in the specification. The polymer of the invention can be used as an alignment material in liquid crystal displays.

Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.

Abstract: Embodiments of a system and method for testing an integrated circuit module comprising multiple integrated circuit devices, such as a memory module comprising multiple memory devices for example, is disclosed. Embodiments of the method may be employed to test an integrated circuit device of the integrated circuit module that provides a data strobe signal associated with at least one data signal provided by the same integrated circuit device. A determination of a test outcome for the integrated circuit module may be made after identifying data valid windows for each integrated circuit device, without having to both identify a common sampling window defined by an intersection of the identified data valid windows and verify that such common sampling window meets specification requirements, as may be performed by conventional testers.

Abstract: Methods and compositions are provided for treating cancer, the methods including the step administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.

Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.

Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.

Abstract: Embodiments of an apparatus and method for high-speed testing of a device under test are described herein, where the device under test is coupled to a tester via a limited passband communication channel. A plurality of test vector patterns is generated having characteristics such that when a given test vector pattern is transmitted electrically at a transmission rate via the communication channel, the test vector pattern has a frequency content that is less than the frequency content of a high frequency test vector pattern if the high frequency test vector pattern were to be transmitted electrically at the transmission rate via the communication channel, and such that the frequency content of each test vector pattern when transmitted electrically at the transmission rate via the communication channel falls within the passband associated with the communication channel.

Abstract: The present invention concerns certain hydrolytic thalidomide metabolites, combinations thereof with other anti-neoplastic compounds and their use in the treatment of solid tumours.

Abstract: A battery connector includes a dielectric housing defining terminal grooves therein to receive plenty of electric terminals. The tops of two sidewalls of each terminal groove extend inwardly to form a pair of withstanding beams. A gap is formed on the front end of the withstanding beam. The electric terminal has a base. The rear end of the base bends upwardly to form a spring portion. A contact portion extends from one end of the spring portion. The middle of the front end of the base bends upwardly to form a welded tail portion leaning inwardly. Two project edges extend outwardly from two sides of the top of the welded tail portion. The welded tail portion is located in the front end of the terminal groove with a part exposed outside the front surface. The project edges are located in the gaps and against the front walls of the withstanding beams.

Abstract: The invention relates to a polyimide resin polymer which contains at least one repeating unit selected from those of formula (A-1) and formula (A-2) below as polymerization units, wherein P1, P2, Q1, and Q2 are as defined in the specification. The polymer of the invention can be used as an alignment material in liquid crystal displays.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more of the following ruthenium oxalato compounds I, II, III and IV as an active ingredient. The pharmaceutical composition can be used for the treatment of viral-infected patients or prophylactic treatment of patients at risk from viral infection.

Abstract: The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing said combinations.

Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.

Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.